KevanCliffordHeroldMD

Diabetes, Lipid Metabolism

Professor, Immunobiology, Yale University School of Medicine

Overview of Dr. Herold

Dr. Kevan Herold is an endocrinologist in New Haven, CT and is affiliated with Yale-New Haven Hospital. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice 38 years. Dr. Herold accepts several types of health insurance, listed below. He is one of 58 doctors at Yale-New Haven Hospital who specialize in Endocrinology. He has more than 100 publications and over 500 citings.

Office
789 Howard Avenue 2nd Floor
Dana Building
New Haven, CT 06510
Book by Phone+1(512) 400-3226

Education & Training

University of ChicagoFellowship, Endocrinology, Diabetes, and Metabolism, 1982 - 1986
Temple University HospitalResidency, Internal Medicine, 1979 - 1982
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1979

Certifications & Licensure

NY State Medical License 1998 - 2025
CT State Medical License 2006 - 2024
IL State Medical License 1982 - 1999
PA State Medical License 1981 - 1986
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Clinical Trials

TrialNet Pathway to Prevention of T1D Start of enrollment: 2004 Feb 01
Recruiting
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes Start of enrollment: 2005 Sep 01
Completed
Phase 2
Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes Start of enrollment: 2006 Sep 01
Completed
Phase 2
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus Start of enrollment: 2007 Feb 01
Completed
Phase 3
Treatment With hOKT3gamma1(Ala-Ala) in T1DM Start of enrollment: 2002 May 01
Terminated
Phase 2
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk" Start of enrollment: 2010 Aug 01
Completed
Phase 2
A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II Start of enrollment: 2010 Oct 01
Withdrawn
Phase 2
T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs Start of enrollment: 2010 Nov 01
Completed
Phase 1
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Start of enrollment: 2013 Mar 01
Completed
Phase 2
Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes Start of enrollment: 2012 Jan 01
Completed
Phase 1
A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes Start of enrollment: 2013 Sep 01
Completed
Phase 2
AbATE Follow-Up Study Start of enrollment: 2014 Feb 01
Completed
Type 1 Diabetes Extension Study Start of enrollment: 2016 Aug 18
Recruiting
T1DM Immunotherapy Using Polyclonal Tregs + IL-2 Start of enrollment: 2016 Aug 01
Completed
Phase 1
A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) Start of enrollment: 2018 Oct 24
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

724 citations
Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
Jeffrey A. Bluestone, Jane H. Buckner, Mark Fitch, Stephen E. Gitelman, Shipra Gupta
Science Translational Medicine. 2015-11-25
72 citations
Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clin...
Michael J. Haller, S. Alice Long, J Lori Blanchfield, Desmond A. Schatz, Jay S. Skyler
Diabetes. 2019-06-01
591 citations
Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association.
Richard A. Insel, Jessica L. Dunne, Mark A. Atkinson, Jane L. Chiang, Dana Dabelea
Diabetes Care. 2015-10-01

Journal Articles

A Call for Improved Reporting of Human Islet Characteristics in Research Articles
Steven E Kahn, Kevan C Herold, Maureen Gannon, Diabetologia
Identification and Analysis of Islet Antigen–Specific CD8+ T Cells with T Cell Libraries
Kevan C Herold, Andrea K Steck, The Journal of Immunology
Reprogramming Human T Cell Function and Specificity with Non-Viral Genome Targeting
Neil Romberg, Antoni Ribas, Michael R Lee, Ruby Yu, Gary M Kupfer, Julia Carnevale, Jonathan H Esensten, P Jonathan Li, Han Li, Kevan C Herold, Alexander Marson, Nature
Collateral Damage: Insulin-Dependent Diabetes Induced with Checkpoint Inhibitors
Robert Rushakoff, Zoe Quandt, James Lee, Kevan C Herold, Diabetes Care
Join now to see all

Lectures

Abnormal Neutrophil Signature in the Blood and Pancreas of Presymptomatic and Symptomatic Type 1 Diabetes
New Haven, CT - 6/15/2014

Press Mentions

In a 1st, Scientists Reversed Type 1 Diabetes by Reprogramming a Person's Own Fat CellsOctober 31st, 2024
5 Medical Advances That Will Change Patient CareMay 4th, 2023
Are We Proof That a New Drug to Stop Diseases like Arthritis and Type 1 Diabetes Really DOES Work?April 3rd, 2023
Join now to see all

Grant Support

Human And Translational ImmunologyNational Institute Of Allergy And Infectious Diseases2010–2011
Type 1 Diabetes Trialnet: Clinical Center At Yale University (U01)National Institute Of Diabetes And Digestive And Kidney Diseases2009–2011
Yale Autoimmunity Center Of ExcellenceNational Institute Of Allergy And Infectious Diseases2009–2011
Administrative Core A, Component Of Yale Autoimmunity Center Of ExcellenceNational Institute Of Allergy And Infectious Diseases2009–2011
Innate And Adaptive Immune Responses In Pre-Type 1 DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2010
Phase II Trial Of Hokt3gamma 1 (Ala-Ala) In Type 1 DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2006–2010
Type 1 Diabetes Trialnet: Clinical Center At Columbia UniversityNational Institute Of Diabetes And Digestive And Kidney Diseases2007
Type 1 Diabetes Trialnet: Clin Ctr At Columbia Universi*National Institute Of Diabetes And Digestive And Kidney Diseases2006
Phase II Trial Of Hokt3gamma 1 (Ala-Ala) In IDDMNational Institute Of Diabetes And Digestive And Kidney Diseases2005
Islet Growth In NOD Mice Tolerant To Autoimmune DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2005
Safety And PK Of Hokt3yl (Ala-Ala) In TidmNational Center For Research Resources2005
Islet Transplants With Renal AllograftsNational Center For Research Resources2005
Islet Growth In NOD Mice Tolerant To Autoimmune DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2005
Combination Of Anti-Cd3 And Ag-Specific ImmunotherapyNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2005
Phase II Multiple Dose Treatment Of Type 1 Diabetes Mellitus With Hokt3gammalNational Center For Research Resources2004–2005
Hokt3yl(Ala-Ala) In New Onset Type 1 Diabetes MellitusNational Center For Research Resources2004–2005
Type 1 Diabetes Trialnet: Clin Ctr At Columbia Universi*National Institute Of Diabetes And Digestive And Kidney Diseases2002–2005
Phase I/II Trial Of Hokt3(1(Ala-Ala) In Type 1 DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2004
Hokt3yl (Ala Ala) In New Onset Type I Diabetes MellitusNational Center For Research Resources2000–2002
T Cell Activation And Repertoire In Insulin Dependent Diabetes / Anti CD40L TrialNational Institute Of Allergy And Infectious Diseases1999–2002
Type 1 Diabetes Trialnet:Columbia UniversityNational Institute Of Diabetes And Digestive And Kidney Diseases2001
Clinical Research Training In Immunosuppression And DiabNational Center For Research Resources2000
Diabetes Prevention Trial--Type I DiabetesNational Center For Research Resources1996–1997
Immunoregulation Of IDDMNational Institute Of Diabetes And Digestive And Kidney Diseases1995
Islet Cell Reactive T-Lymphocytes In DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases1994
Immune Mechanism For Preventing Autoimmune DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases1992–1994
Islet Cell Reactive T Lymphocytes In Murine DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases1990–1993

Professional Memberships

American Diabetes Association - ADA
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Connecticare FlexPOS
GHI PPO
Great West PPO
Health Alliance PPO
HIP of New York - Select PPO
Multiplan PHCS PPO
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Wellmark Alliance Select
Please verify your coverage with the provider's office directly when scheduling an appointment